Request for Information (RFI) TPI Direct-to-Manufacturer Prescriptions

HHS0017013

Posted

Estefan Rodriguez

(512) 627-3447

estefan.rodriguez@hhs.texas.gov

4/3/2026

10:30 AM

529

21+ Days for Solicitation Notice

CTCD

2/10/2026

2/10/2026 2:26 pm

26904-Antihistamine Drugs;
26908-Anti-Infective Agents;
26910-Antineoplastic Agents;
26912-Autonomic Drugs;
26924-Cardiovascular Drugs;
26928-Central Nervous System Agents (Including: Analegsic, Anticonvulsant, Antidepressant, Antihistamine, Antipsychotic And Sedative);
26932-Contraceptives;
26956-Gastrointestinal Drugs;
26972-Miscellaneous Drugs And Pharmaceuticals (Not Otherwise Classified);
26987-Therapeutic Agents, Unclassified;
94872-Pharmaceutical Services;
96757-Pharmaceutical And Medical Equipment And Products Manufacturing Services;

District 1,

District 2,

District 3,

District 4,

District 5,

District 6,

District 7,

District 8,

District 9,

District 10,

District 11,

District 12,

District 13,

District 14,

District 15,

District 16,

District 17,

District 18,

District 19,

District 20,

District 21,

District 22,

District 23,

District 24,

District 25

TPI seeks information from entities regarding the direct-to-manufacturer purchase of prescription pharmaceuticals. For purposes of this RFI, assume the purchase would involve at least one State of Texas employee and retiree health plan.